Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Chronic%20myeloid%20leukemia News

News

Dasatinib beneficial to leukaemia patients with suboptimal response to imatinib

20200817060000

In patients with chronic myeloid leukaemia (CML) in chronic phase (CP) who have not achieved molecular response with first-line imatinib at 3 months, early switching to dasatinib increases the chances of achieving major molecular response (MMR) at 12 months, according to data from the phase IIb DASCERN trial.

COVID-19 recommendations in 23 languages for cancer patients

Christina Lau, 20200707054248

Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]

Asciminib shows therapeutic potential in chronic myeloid leukaemia

20200328080000

The allosteric inhibitor asciminib shows clinical activity in heavily pretreated patients with chronic myeloid leukaemia who have failed or cannot tolerate tyrosine kinase inhibitors, including those who do not respond to ponatinib and harbour a T315I mutation, according to the results of a phase I dose-escalation study.

Dengue infection tied to raised leukaemia risk

Roshini Claire Anthony, 20200309140103

Individuals with a history of dengue infection may have a twofold risk of developing leukaemia 3–6 years post-infection, according to a population-based cohort study from Taiwan.

TKI treatment discontinuation in chronic myeloid leukaemia feasible in clinical practice

20190118110000

Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

First-line imatinib highly effective for paediatric chronic myeloid leukaemia

Jairia Dela Cruz, 20180806100000

Use of imatinib in the first-line treatment of children and adolescents with chronic myeloid leukaemia (CML) appears highly effective, yielding excellent response with tolerable side effects, according to the results of a single-arm phase III trial.

BFORE: Bosutinib remains superior to imatinib in CML at 2 years

Jairia Dela Cruz, 20180620100000

Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.

Cognitive impairment linked to worse survival in elderly with haematologic cancers

Christina Lau, 20180309060010

Cognitive dysfunction is associated with reduced survival in elderly patients with haematologic malignancies, a recent study has shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

Individualized starting dose of niraparib effective, well tolerated in Chinese patients with recurrent ovarian cancer

Dr Margaret Shi, 09 Oct 2020

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

Dr Margaret Shi, 14 May 2020

Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.